Share Email Print

Proceedings Paper

CGP 55 847, liposome-delivered zinc(II)-phthalocyanine as a phototherapeutic agent for tumors
Author(s): Klaus Schieweck; Hans-Georg Capraro; Ute Isele; Peter van Hoogevest; Martin Ochsner; Thomas Maurer; Ernst Batt
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Zinc(II)-phthalocyanine (Zn-Pc) was chosen for development as a second-generation photosensitizer for photodynamic therapy (PDT) of tumors and for benign conditions because of its advantageous chemical and photophysical properties. Zn-Pc displayed good selectivity for malignant tissue in pharmacokinetic studies with Meth-A-sarcoma-bearing BALB/c mice when injected in a dose of 0.125 mg/kg, delivered by CGP 55 847. Intravenous doses of Zn- Pc ranging from 0.032 to 0.375 mg/kg caused tumor necrosis and, subsequently, cure of Meth-A-sarcoma-bearing mice when phototreatment was performed 48 hours after injection of CGP 55 847. Intravenous injection of Zn-Pc into hairless mice in doses ranging from 0.1 to 1.0 mg/kg caused dose- and time-dependent phototoxicity. We conclude that the promising pharmacological properties of liposomally delivered Zn-Pc, along with its advantageous chemical and photophysical properties, warrant the development of CGP 55 847 as a candidate drug for photodynamic therapy of tumors in humans.

Paper Details

Date Published: 1 March 1994
PDF: 12 pages
Proc. SPIE 2078, Photodynamic Therapy of Cancer, (1 March 1994); doi: 10.1117/12.168675
Show Author Affiliations
Klaus Schieweck, CIBA-GEIGY Ltd. (Switzerland)
Hans-Georg Capraro, CIBA-GEIGY Ltd. (Switzerland)
Ute Isele, CIBA-GEIGY Ltd. (Switzerland)
Peter van Hoogevest, CIBA-GEIGY Ltd. (Switzerland)
Martin Ochsner, CIBA-GEIGY Ltd. (Switzerland)
Thomas Maurer, CIBA-GEIGY Ltd. (Switzerland)
Ernst Batt, CIBA-GEIGY Ltd. (Switzerland)

Published in SPIE Proceedings Vol. 2078:
Photodynamic Therapy of Cancer
Giulio Jori; Johan Moan; Willem M. Star, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?